Urothelial Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Not yet recruiting
  • Urothelial Cancer
  • +4 more
    • Washington, District of Columbia
    • +2 more
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Urothelial Cancer
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    A
    Recruiting
    • Carcinoma, Transitional Cell
    • +6 more
    • enfortumab vedotin (EV)
    • +4 more
    • Anchorage, Alaska
    • +105 more
    2022-04-06
    Apr 6, 2022
    N
    Recruiting
    • Urothelial Carcinoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Bladder Cancer
    • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-04-07
      Apr 7, 2022
      P
      Recruiting
      • Advanced Malignancies
      • +4 more
      • Chermside, Queensland, Australia
      • +10 more
      2022-04-04
      Apr 4, 2022
      A
      Active, not recruiting
      • Ureteral Cancer
      • +2 more
      • Enfortumab Vedotin
      • +3 more
      • Orange, California
      • +157 more
      2022-03-29
      Mar 29, 2022
      A
      Recruiting
      • Urothelial Cancer
      • Enfortumab vedotin
      • +4 more
      • Chandler, Arizona
      • +189 more
      2022-03-28
      Mar 28, 2022
      N
      Completed
      • Cervical Cancer
      • +4 more
      • Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-03-02
      Mar 2, 2022
      J
      Recruiting
      • Urothelial Cancer
      • Scottsdale, Arizona
      • +160 more
      2022-03-24
      Mar 24, 2022
      J
      Recruiting
      • Urothelial Cancer
      • Receptors, Fibroblast Growth Factor
      • Archival Tumor Tissue Sample
      • Tucson, Arizona
      • +220 more
      2022-03-24
      Mar 24, 2022
      I
      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +4 more
      • Plovdiv, Bulgaria
      • +11 more
      2022-03-24
      Mar 24, 2022
      A
      Active, not recruiting
      • Urothelial Cancer
      • MEDI4736 (Durvalumab)
      • +4 more
      • Los Angeles, California
      • +221 more
      2022-03-22
      Mar 22, 2022
      N
      Terminated
      • Urothelial Cancer
      • Bintrafusp alfa (M7824)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-02-25
      Feb 25, 2022
      N
      Recruiting
      • NSCLC, Non Small Cell Lung Cancer
      • +9 more
      • Santa Monica, California
      • +22 more
      2022-03-18
      Mar 18, 2022
      P
      Recruiting
      • Squamous Cell Carcinoma of the Head and Neck
      • +10 more
      • Scottsdale, Arizona
      • +31 more
      2022-03-18
      Mar 18, 2022
      I
      Recruiting
      • Urothelial Cancer
      • Metastatic Solid Tumor
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      2022-03-05
      Mar 5, 2022
      S
      Not yet recruiting
      • Urothelial Cancer
      • Huelva, Andalucia, Spain
      • +11 more
      2022-03-09
      Mar 9, 2022
      M
      Completed
      • Urothelial Cancer
      • pembrolizumab
      • (no location specified)
      2022-02-24
      Feb 24, 2022
      P
      Recruiting
      • Advanced Solid Tumors
      • +5 more
      • Grand Rapids, Michigan
      • +4 more
      2022-03-03
      Mar 3, 2022
      D
      Recruiting
      • Melanoma
      • +7 more
      • Nivolumab or Pembrolizumab (dependent upon approved indication)
      • +2 more
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      2022-02-10
      Feb 10, 2022
      F
      Recruiting
      • Urothelial Cancer
      • Niraparib plus Cabozantinib
      • Barcelona, Cataluña, Spain
      • +10 more
      2022-02-08
      Feb 8, 2022
      E
      Active, not recruiting
      • Urothelial Cancer
      • Bergamo, Italy
      • +4 more
      2022-01-25
      Jan 25, 2022